Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective studyKatia Mattarozzi, Michele Santangelo, Susanna Malagù et al.|International Journal of Clinical Practice|2012Cited by 20
High dose intravenous immune globulins and plasma exchange in Guillain-Barré SyndromeAlessandro Ravasio, Vanessa Fadanelli Schoenardie Poli, Marco Pasquinelli et al.|The Italian Journal of Neurological Sciences|1995Cited by 18
ASPIRE interferon beta-1b in combination with azathioprine for secondary progressive multiple sclerosis: a 2-year, double blind, randomizesed, multicentre, pilot study. EDSS; MSQOL54 and safety dataE. Montanari, Luca Durelli, L. Manneschi et al.|Unknown|2004Cited by 0
ASPIRE interferon beta 1-b in combination with azathioprine for secondary progressive multiple sclerosis: a 2-year double blind, randomized, multicentre, pilot study. Safety and drop-outs data at 21 month of enrollementL. Manneschi, E. Montanari, Ilaria Pesci et al.|Unknown|2006Cited by 0
Interferon beta 1-b in combination with azathioprine for secondary progressive multiple sclerosis. preliminary safety and tolerability data from a 2-year double blind, randomized, multicentre, pilot study.L. Manneschi, Luca Durelli, Ilaria Pesci et al.|Unknown|2004Cited by 0